Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (AVXL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
avxl · stock forecast · 13 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$11.00
Consensus
$11.00
+319.8% upside
Low
$11.00
Median: $11 · Last Close: $2.62
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Short-term predictions are paused during the ±3-day earnings window to avoid unreliable signals.
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -25.5% |
| 2028 | $2 | -35.0% |
| 2029 | $2 | -39.2% |
| 2030 | $2 | -41.1% |
| 2031 | — | -42.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AVXL · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-31 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-26 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-23 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-09 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-06 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-19 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-12-15 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Anavex Life Sciences Corp. (AVXL) stock. Of the recent 73 rating actions, 0 were upgrades and 2 were downgrades. 13 analysts currently cover AVXL.
Analyst Recommendation Trends
AVXL analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$776M
↑ 122.6% YoY
Revenue Next Year
$1.2B
↑ 55.9% YoY
EPS This Year
$-0.33
EPS Next Year
$-0.55
↑ 66.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast AVXL EPS of $-0.33 for the current fiscal year, based on estimates from 1 analysts. The AVXL revenue forecast is $776M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AVXL stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AVXL price target is $11.00 (+319.8% upside), with an analyst consensus of Buy.
The AVXL stock price prediction for 2027 estimates an average of $2. The AVXL stock prediction for 2030 projects a range of $1–$2.
Anavex Life Sciences Corp. trades on NASDAQ under the ticker AVXL. The AVXL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 85% of covering analysts.
Frequently asked questions
AVXL forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month AVXL price target is $11.00, with a high forecast of $11.00 and a low of $11.00. The median price target is shown in the chart above when available. This implies +319.8% potential upside from the current price of $2.62.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.